CARsgen Therapeutics Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

Shanghai China

Primary Industry

Biotechnology

About

Established in 2014 and based in Shanghai, China, CARsgen Therapeutics Co., Ltd. operates as a biopharmaceutical company that focuses on chimeric antigen receptor t-cell(CAR-T) cell therapy to treat hematomas and solid tumors. The company provides cell therapy platform that includes target discovery, lead antibody development, clinical research and commercial scale production. The product of the company includes manand biosphere programme(mAb) and the regular, next generation and Allogeneic of cell therapy products, such as AB011, KJ-C2112 and CT011. The company develops cytokine and chemokine loaded CAR(CycloCAR), target to hinder the attack of nk cell(THANK)-uCAR and whole human anti-phage display technology. The company has 7 investigational new drug(IND)licenses.

Current Investors

Photon Fund, Lilly Asia Ventures, South China Venture Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment

Website

www.carsgen.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.